Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Wockhardt sells Baddi...

    Wockhardt sells Baddi plant, 62 drug brands to Dr Reddys for Rs 1850 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-12T17:23:20+05:30  |  Updated On 12 Feb 2020 5:23 PM IST
    Wockhardt sells Baddi plant, 62 drug brands to Dr Reddys for Rs 1850 crore

    Commenting on the acquisition, Dr Reddy's Co-Chairman and Managing Director G V Prasad said," the acquired portfolio shall enhance Dr Reddy''s presence in the high growth therapy areas with market-leading brands such as Practin, Zedex, Bro-zedex, Tryptomer and Biovac. We believe the portfolio holds a lot of potentials and will get an impetus under Dr Reddy's."

    New Delhi: Pharma major Wockhardt Ltd on Wednesday announced the sale of select divisions of branded generics business in India and four other countries to Dr Reddy''s Laboratories for Rs 1,850 crore.

    Besides India, the four countries are Nepal, Sri Lanka, Bhutan and Maldives.

    The business comprises of a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, dermatology, gastroenterology, pain and vaccines, among others which would be transferred to Dr Reddy's along with related sales and marketing teams, the two companies said in separate regulatory filings.

    The acquisition would also include Wockhardt's manufacturing plant located in Baddi in Himachal Pradesh along with all plant employees. The business undertaking is being transferred on a slump-sale basis, the filing added.

    Wockhardt said revenue from business undertaking proposed to be transferred was Rs 594 crore during FY2018-19, and Rs 377 crore during the nine-month period of the ongoing fiscal ended December 31, 2019.

    Wockhardt Group Founder Chairman Habil Khorakiwala said the intended sale of business portfolio is in line with the company's strategic plan to shift from acute therapeutic areas to more chronic business like anti-diabetes, central nervous system (CNS) and also to its niche antibiotic portfolio of new chemical entities (NCEs).

    "The divestment will also ensure adequate liquidity to bring in robust growth in the chronic domestic branded business, international operations, investments in Biosimilars for the US market apart from the company's global clinical trials of Break-through Anti-infectives (NCEs approved under coveted QIDP1 program of United States Food & Drug Administration) and R&D activities," he added.

    Commenting on the acquisition, Dr Reddy's Co-Chairman and Managing Director G V Prasad said, "India is an important market for us and this acquisition will help in considerably scaling-up our domestic business."

    He further said, "the acquired portfolio shall enhance Dr Reddy''s presence in the high growth therapy areas with market-leading brands such as Practin, Zedex, Bro-zedex, Tryptomer and Biovac. We believe the portfolio holds a lot of potentials and will get an impetus under Dr Reddy's."

    The transaction is expected to be closed in the first quarter of the financial year 2020-21.

    After the sale of the select business, Wockhardt said it would continue to own all international operations in UK, USA, Ireland and other locations through its step down subsidiaries.

    The formulation plants located at Waluj, Shendra and Chikalthana in Aurangabad, Bhimpore and Kadaiya in Daman; bulk drugs plant at Ankleshwar, India and manufacturing facilities at all existing international locations would also continue to be owned by the company.

    Wockhardt said its research and development centres located at Chikalthana, Aurangabad, India and existing facilities in the international locations would also continue to be under its fold along with a significant part of domestic branded business constituting chronic and speciality portfolios.

    Read also: Wockhardt gets DCGI nod for 2 new antibiotics

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok